Key Insights

Highlights

Success Rate

93% trial completion (above average)

Published Results

13 trials with published results (21%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

4.9%

3 terminated out of 61 trials

Success Rate

93.3%

+6.8% vs benchmark

Late-Stage Pipeline

48%

29 trials in Phase 3/4

Results Transparency

31%

13 of 42 completed with results

Key Signals

13 with results93% success

Data Visualizations

Phase Distribution

48Total
Not Applicable (10)
P 1 (7)
P 2 (2)
P 3 (23)
P 4 (6)

Trial Status

Completed42
Unknown10
Recruiting5
Terminated3
Not Yet Recruiting1

Trial Success Rate

93.3%

Benchmark: 86.5%

Based on 42 completed trials

Clinical Trials (61)

Showing 20 of 20 trials
NCT07312370Phase 4Not Yet Recruiting

Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing

NCT03553563Phase 3Completed

A Study of Esomeplazole (D961H) in Japanese Paediatric Patients With Reflux Esophagitis, Gastric Ulcer or Duodenal Ulcer

NCT07385235Phase 1RecruitingPrimary

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

NCT06902818Phase 1CompletedPrimary

The Study Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

NCT06848400Not ApplicableRecruiting

Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios

NCT07032961Recruiting

A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies Screening

NCT06822413Recruiting

Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis

NCT05656092Phase 3CompletedPrimary

A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer

NCT06642987Phase 1CompletedPrimary

Study to Evaluate the Bioequivalence of Vonopzan Tablet 20mg(Vonoprazan Fumarate) and Vocinti Tablet 20mg in Healthy Adult Subjects.

NCT05448001Phase 3CompletedPrimary

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

NCT05518929Phase 4CompletedPrimary

Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients

NCT06167226Completed

Understanding Ayurveda Disease Conditions and Treatment Responses

NCT05579444Terminated

Systems Biology of Gastrointestinal and Related Diseases

NCT04724291Not ApplicableCompleted

MAGNET (Magnetically Controlled Capsule for Assessment of Gastric Mucosa in Symptomatic Patients)

NCT05517408Not ApplicableUnknown

Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.

NCT05526339Not ApplicableUnknown

HFNO Combined With NPA Reduces Hypoxia During Sedated Gastrointestinal Endoscopy In Obese Patients

NCT03972956Recruiting

Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease

NCT03060746Completed

Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects

NCT03050307Phase 3CompletedPrimary

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection

NCT04885751Phase 4Unknown

Compare the Effect of Eupatilin and Rebamipide on the Prevention of Gastroenteropathy

Scroll to load more

Research Network

Activity Timeline